Boston Scientific and Angiotech Win Patent Infringement Case Against Sahajanand in the Netherlands
Boston Scientific Corporation and Angiotech Pharmaceuticals, Inc. announced that they received a favorable decision from a Dutch court in a patent dispute against Sahajanand Medical Technologies Pvt. Ltd. Boston Scientific and Angiotech alleged that Sahajanand's Infinnium paclitaxel-eluting stent infringed two claims of an Angiotech patent directed to paclitaxel stents. The Court found that the asserted claims were infringed and valid.
The Court granted Boston Scientific and Angiotech an injunction against Sahajanand, prohibiting the company from selling, bringing onto the market and delivering -- as well as importing, offering or keeping in stock for one of these purposes -- the infringing Infinnium paclitaxel stent in the Netherlands. The Court also ordered Sahajanand to pay damages and/or surrender profits resulting from the infringement. The Court's decision can be appealed by Sahajanand.
Most read news
Organizations
Other news from the department politics & laws

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

How well masks protect - A detailed study shows the maximum risks of being infected by the coronavirus for different scenarios with and without masks

Shining some light on the obscure proteome - Chemoproteomics draw the target landscape of HDAC drugs
Cellexus Biosystems appoints Dr Julie Bick as its US-based Chief Scientific Officer

Urinary tract infection: How bacteria nestle in

Cell atlas of the aging lung

New Chance for Better Pandemic Response - Researchers succeed in developing neutralizing anti-SARS-CoV-2 antibodies from immune cells of healthy donors

Link between bacteria metabolism and communication could pave way for new antivirulence drugs

Merck Confirms Guidance for 2022 and Delivers Strong Organic Growth in Q3 - Merck continued to grow despite a challenging external operating environment
New tool illuminates connections between stem cells and cancer
